

A Bio-NMR Workshop, Bio-NMR - Industry Cooperation

26th-27th January, 2012, CERM, University of Florence - Italy

Draft Agenda January 27th, 2012

- Welcome and scope of the meeting (I. Bertini, 10 min)
- Overview over Bio-NMR (CERM, 10 min)
- Access models to Research Infrastructures for industry on examples (H. Schwalbe, 15 min)
- Importance of NMR for industries in biotech and biomedicine (C. Griesinger, 10 min)
- The IT serving industries (A. Bonvin, 15 min)

Coffee break (15 min)

- Talks by Industry (20+10 min each)
 - V. Mikol (Sanofi-Aventis): Structural Biology in Drug Discovery; a Global assessment
 - M. Nissum (Novartis Vaccines): Integrated Structural Biology in Vaccinology, a case study
 - M. Spraul (Bruker): Developments in instrumentation, automation, analysis, technologies
 - Space for short statements from industry representatives.

Lunch (1 hour)

Round table on:

Requirements for Industry to access and obtain services from biological NMR facilities and models of their use.

- Requirements for confidentially procedures (F. Uggeri, Bracco)
- Need for European funding initiatives (chaired by P. Tompa and H. Oschkinat)
- Summary of results, future actions (L. Banci)

A Bio-NMR Workshop, Bio-NMR - Industry Cooperation

26th-27th January, 2012, CERM, University of Florence - Italy

Participants (Bio-NMR)

CERM (I. Bertini, L. Banci, C. Luchinat)

MPI (C. Griesinger)

BMRZ (H. Schwalbe)

UU (A. Bonvin)

FMP (H. Oschkinat)

ENZIM (P. Tompa)

Spronk-NMR (K. Lesickas)

SLONMR (P. Sket, M. Polak)

Participants (Industry)

V. Mikol (Sanofi-Aventis)

M. Nissum (Novartis Vaccines)

A. Aramini (Dompé)

A. Padova, E. Genesio (SienaBiotech)

K. Seidel (BASF Pharma)

B. Gewiese, M. Spraul (Bruker)

F. Uggeri (Bracco)

R. Meinecke (Boehringer Ingelheim)

A. Müller-Fahrnow (Bayer Pharma)

M. Giusti (Eli Lilly)

C. Marchioro (Aptuit)